is this you? Claim your profile.
is this you? Claim your profile.
Business Development Director
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
Global Biodefence for PowderJect Pharmaceuticals Plc
Chief Executive Officer
Su-Peing Ng, CEO, CorticalSu brings to Cortical international biotechnology business development and commercial strategy experience.Prior to joining Cortical, she was Business Development Director for Chiron Vaccines - a division of Chiron Corporation - dedicated to Chiron's US$330m+ influenza franchise and held various business development roles with PowderJect Pharmaceuticals Plc, including Director of Global Biodefence for PowderJect Pharmaceuticals Plc, where she developed the business strategy to enable PowderJect to expand within the growing market for biodefence vaccines.She has also developed in-licensing, sales and marketing strategies for various vaccines and immunotherapies, and led corporate strategic planning activities.
Cortical's board of management has welcomed Dr Su-Peing Ng who joined the company as CEO on 19 August 2004.Dr Ng joins Cortical having recently returned from the UK where she was Business Development Director for Chiron Vaccines responsible for the company's US$300m influenza franchise.Cortical's core strengths are medicinal chemistry, applied biology and virtual drug development.Dr Ng brings to the company several years of international pharmaceutical and biotechnology business and commercial strategy development experience.Dr Ng is a qualified medical practitioner and holds an MBA from the Melbourne Business School where she graduated with distinction.As part of her MBA program, Dr Ng studied at the Fuqua Business School at Duke University.Dr Ng's mission for Cortical is to expand the pipeline beyond the current focus of macrophage migratory inhibitory factor (MIF) to include other molecules with potential anti-inflammatory effects.In early October (6th - 7th), Dr Ng will participate in an Australian Biotechnology Mission to the Medicon Valley conference at Bella Center in Copenhagen."As a niche Australian biotechnology company, the mission provides an ideal opportunity to showcase our research and development activities and to meet other prospective research and commercialisation partners.I am very pleased to be part of this initiative," said Dr Ng.For further information, or to arrange an interview with Dr Su-Peing Ng, please contact Katrina Weir on (02) 9436 2088 or email email@example.com.
Cortical's board of management has welcomed Dr Su-Peing Ng who joined the company as CEO on 19 August 2004.
Cortical's CEO Dr Su-Peing Ng, is delighted that the company has been awarded the grant, and particularly pleased that AusIndustry has recognised the potential benefits of Cortical's R&D program.
"Competition for R&D START grants is extremely high and we are grateful to AusIndustry for their support," Dr Ng said "Cortical is developing and soon to commence the trial of potent oral MIF antagonist drugs, which have the potential to provide a more effective solution for patients," Dr Ng explained. For further information, or to arrange an interview with Dr Su-Peing Ng, please contact Katrina Weir on (02) 9436 2088 or email firstname.lastname@example.org.